Rituximab

Generic Name: Rituximab

Brand Names: MabThera, Riabni, Rituxan, Rituxan Hycela, Ruxience, Truxima, Blitzima, Rixathon, Riximyo

Drug Type: Biotech

Chemical Formula: -

CAS Number: 174722-31-7

Unique Ingredient Identifier: 4F4X42SYQ6

Background: Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences , . It was originally approved by the U...

Indication: Rituximab is indicated for the treatment of adult patients with relapsed or refractory, low-grade or follicular, CD20-positive, B-cell non-Hodgkin’s Lymphoma (NHL) as a single agent. Also, it is indicated for the treatment of adult patients with previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in pat...

Associated Conditions: Active, Moderate to Severe Rheumatoid Arthritis, Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Non-Hodgkin's Lymphoma, Granulomatosis With Polyangiitis, Microscopic Polyangiitis (MPA), Advanced Burkitt Lymphoma (BL), Advanced Burkitt-like lymphoma, Advanced Diffuse Large B-Cell Lymphoma (DLBCL), Advanced Mature B-cell type acute leukaemia, Moderate Pemphigus Vulgaris (PV), Non-progressive Low Grade Non-Hodgkin's Lymphoma (NHL), Refractory Low Grade Non-Hodgkin's Lymphoma (NHL), Refractory follicular B-cell non-Hodgkin's lymphoma, Relapsed Low Grade Non-Hodgkin's Lymphoma (NHL), Relapsed follicular B-cell non-Hodgkin's lymphoma, Severe Pemphigus Vulgaris (PV)

Associated Therapies: -

Clinical Trials

Comparing Interleukin-2 (IL-2) Combined With Rituximab (Rituxan) to Rituximab Alone in Subjects With Non-Hodgkin's Lymphoma (NHL)

Phase 2

Terminated

Conditions: Non-Hodgkin Lymphoma

First Posted Date: 2005-01-07

Last Posted Date: 2006-02-06

Lead Sponsor: Chiron Corporation

Target Recruit Count: 300

Registration Number: NCT00100737

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

A Study to Evaluate Rituximab in Adults With Relapsing Remitting Multiple Sclerosis

Phase 2

Completed

Conditions: Multiple Sclerosis

First Posted Date: 2004-11-19

Last Posted Date: 2014-03-04

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 104

Registration Number: NCT00097188

Locations: 🇺🇸
Michigan Institute For Neurological Disorders, Farmington Hills, Michigan, United States
🇺🇸
Neurology and Neuroscience Assoc.,INC, Akron, Ohio, United States
🇺🇸
MS Center of Vero Beach, Vero Beach, Florida, United States

and more 28 locations

Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity

Phase 2

Active, not recruiting

Conditions: Lymphoproliferative Disorder
HIV
HHV-8
Malignancy

Interventions: Drug: Etoposide
Drug: Interferon-alpha
Other: Observation Only
Drug: Sirolimus
Drug: Zidovudine
Drug: Rituximab
Drug: Bortezomib
Drug: Doxorubicin
Drug: Liposomal Doxorubicin
Drug: Valganciclovir
Drug: Vincristine
Drug: Cyclophosphamide
Drug: Filgrastim (G-CSF)
Drug: Prednisone

First Posted Date: 2004-09-22

Last Posted Date: 2024-12-19

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 75

Registration Number: NCT00092222

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Rituximab to Treat Stiff Person Syndrome

Phase 2

Completed

Conditions: Stiff Person Syndrome

Interventions: Drug: Rituximab
Drug: rituximab or placebo

First Posted Date: 2004-09-20

Last Posted Date: 2011-08-31

Lead Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)

Target Recruit Count: 24

Registration Number: NCT00091897

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients

Phase 3

Completed

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Rituximab
Drug: Fludarabine Phosphate
Drug: Cyclophosphamide

First Posted Date: 2004-08-25

Last Posted Date: 2017-08-01

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 552

Registration Number: NCT00090051

Locations: 🇪🇸
Hospital Clinico Universitario de Salamanca;Servicio de Hematologia, Salamanca, Spain
🇺🇸
Rush-Presbyterian St. Luke'S Medical Center, Chicago, Illinois, United States
🇨🇦
Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada

and more 103 locations

Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma

Phase 4

Completed

Conditions: Non-Hodgkin's Lymphoma

Interventions: Drug: rituximab

First Posted Date: 2004-08-24

Last Posted Date: 2009-10-20

Lead Sponsor: Biogen

Target Recruit Count: 168

Registration Number: NCT00090038

Locations: 🇺🇸
USC KECK School of Medicine, Los Angeles, California, United States
🇺🇸
Tufts - New England Medical Center, Boston, Massachusetts, United States
🇺🇸
Our Lady of Mercy Medical Center, Bronx, New York, United States

and more 5 locations

Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20+ NHL

Phase 1

Terminated

Conditions: Non-Hodgkin's Lymphoma (NHL)

Interventions: Drug: Rituxan
Drug: motexafin gadolinium
Drug: 111Indium-Zevalin and 90Yttrium-Zevalin

First Posted Date: 2004-08-05

Last Posted Date: 2019-08-14

Lead Sponsor: Northwestern University

Target Recruit Count: 30

Registration Number: NCT00089284

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
Jesse B. Brown Veterans Affairs Medical Center, Chicago, Illinois, United States

A Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary Progressive Multiple Sclerosis

Phase 2

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: rituximab
Drug: placebo

First Posted Date: 2004-07-13

Last Posted Date: 2015-09-09

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 439

Registration Number: NCT00087529

Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL)

Phase 2

Completed

Conditions: Chronic Lymphocytic Leukemia

First Posted Date: 2004-06-29

Last Posted Date: 2015-03-25

Lead Sponsor: Point Therapeutics

Registration Number: NCT00086203

Locations: 🇺🇸
Cancer Care Associates--Tulsa, Tulsa, Oklahoma, United States
🇺🇸
Queens Medical Associates, PC, Fresh Meadows, New York, United States
🇺🇸
Hematology/Oncology Centers of the Northern Rockies, Billings, Montana, United States

and more 16 locations

Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma

Phase 3

Completed

Conditions: Lymphoma

First Posted Date: 2004-05-25

Last Posted Date: 2023-12-27

Lead Sponsor: University of Nebraska

Registration Number: NCT00004112

Locations: 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy